Eton Pharmaceutcials Inc (ETON) Stock Price, Quote & News

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 847 787 7361

Website: www.etonpharma.com

Address:

21925 W. Field Parkway, Suite 235, Deer Park, United States

TRISTANX17 Mar. 21 at 11:36 PM

$ETON

0 · Reply

Merlintrader Mar. 21 at 8:42 PM

$ETON https://www.merlintrader.com/biotech-stocks-saga/

0 · Reply

Cacaos Mar. 21 at 12:53 AM

$ETON under the radar. Time to sell ?

0 · Reply

Jimbates22 Mar. 20 at 8:50 PM

$ETON this was a good run considering the market. Sold my calls today for a nice profit. GLTA who are still in. I would still be bullish but I think there are better uses of capital at the moment.

0 · Reply

Stackdoe101 Mar. 20 at 7:36 PM

$ETON 🙃✨

0 · Reply

topstockalerts Mar. 20 at 7:26 PM

$ETON tends to react when something hits the tape, not a constant mover. When it goes, it usually has intent behind it.

0 · Reply

MoonPetal Mar. 20 at 6:52 PM

$ETON 30$

0 · Reply

CharlieeMungerTWITS Mar. 20 at 5:33 PM

$ETON the gut is the gut

1 · Reply

CharlieeMungerTWITS Mar. 20 at 5:29 PM

$ETON wow congrats guys! What a sick hold

0 · Reply

topstockalerts Mar. 20 at 5:26 PM

$ETON tends to react to catalysts, not a constant mover. When it gets going, it usually has a reason.

0 · Reply

Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript

Mar 19, 2026, 4:05 PM EDT - 2 days ago

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 3, 2026, 4:30 PM EST - 18 days ago

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Mar 2, 2026, 7:27 AM EST - 19 days ago

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Feb 25, 2026, 1:51 PM EST - 24 days ago

US FDA approves Eton Pharma's hormonal disorder drug

Feb 25, 2026, 1:47 PM EST - 24 days ago

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

Feb 20, 2026, 6:50 AM EST - 4 weeks ago

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

Feb 2, 2026, 6:50 AM EST - 6 weeks ago

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Jan 23, 2026, 10:20 AM EST - 2 months ago

Eton Pharmaceuticals: An Undervalued Small Cap With High Growth

Nov 24, 2025, 4:30 PM EST - 4 months ago

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

Nov 12, 2025, 4:30 PM EST - 4 months ago

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Nov 6, 2025, 11:16 PM EST - 4 months ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:30 PM EDT - 5 months ago

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Aug 20, 2025, 6:50 AM EDT - 7 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Aug 8, 2025, 3:27 PM EDT - 8 months ago

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:02 AM EDT - 8 months ago

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 7:00 AM EDT - 8 months ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 9:33 AM EDT - 8 months ago

Eton Pharma Near Term Catalysts Vanish

Jul 8, 2025, 6:50 AM EDT - 9 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Jun 27, 2025, 6:50 AM EDT - 9 months ago

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 6, 2025, 5:26 PM EDT - 10 months ago

Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

May 29, 2025, 12:42 PM EDT - 10 months ago

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

May 28, 2025, 5:28 PM EDT - 10 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

May 21, 2025, 2:57 AM EDT - 10 months ago

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche

May 14, 2025, 4:30 PM EDT - 11 months ago

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

May 13, 2025, 10:40 PM EDT - 11 months ago

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 11 months ago

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

May 1, 2025, 4:30 PM EDT - 11 months ago

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 28, 2025, 6:50 AM EDT - 11 months ago

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Mar 25, 2025, 2:30 AM EDT - 1 year ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Mar 18, 2025, 7:42 PM EDT - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

Mar 18, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Mar 14, 2025, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Mar 4, 2025, 10:00 AM EST - 1 year ago

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Mar 4, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Mar 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Feb 7, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Feb 6, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Jan 3, 2025, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Dec 20, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Dec 3, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Nov 25, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Nov 12, 2024, 8:01 PM EST - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 3, 2024, 6:30 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

TRISTANX17 Mar. 21 at 11:36 PM

$ETON

0 · Reply

Merlintrader Mar. 21 at 8:42 PM

$ETON https://www.merlintrader.com/biotech-stocks-saga/

0 · Reply

Cacaos Mar. 21 at 12:53 AM

$ETON under the radar. Time to sell ?

0 · Reply

Jimbates22 Mar. 20 at 8:50 PM

$ETON this was a good run considering the market. Sold my calls today for a nice profit. GLTA who are still in. I would still be bullish but I think there are better uses of capital at the moment.

0 · Reply

Stackdoe101 Mar. 20 at 7:36 PM

$ETON 🙃✨

0 · Reply

topstockalerts Mar. 20 at 7:26 PM

$ETON tends to react when something hits the tape, not a constant mover. When it goes, it usually has intent behind it.

0 · Reply

MoonPetal Mar. 20 at 6:52 PM

$ETON 30$

0 · Reply

CharlieeMungerTWITS Mar. 20 at 5:33 PM

$ETON the gut is the gut

1 · Reply

CharlieeMungerTWITS Mar. 20 at 5:29 PM

$ETON wow congrats guys! What a sick hold

0 · Reply

topstockalerts Mar. 20 at 5:26 PM

$ETON tends to react to catalysts, not a constant mover. When it gets going, it usually has a reason.

0 · Reply

oaksapollo Mar. 20 at 5:22 PM

$ETON I wrote some March $22.50 covered calls that expire today

0 · Reply

IN0V8 Mar. 20 at 3:51 PM

$ETON Buy B. Riley raises target price to $31 from $26

0 · Reply

CharlieeMungerTWITS Mar. 20 at 10:48 AM

$ETON wowza. Absolute beast mode since February. I freaking love bio

0 · Reply

BioSpecialOne Mar. 20 at 10:02 AM

$ETON 😎🫵🏻

0 · Reply

Jimbates22 Mar. 20 at 3:06 AM

$ETON https://evranic.substack.com/p/eton-pharmaceuticals-reported-q4

0 · Reply

StocktwitsEarnings Mar. 19 at 9:18 PM

$ETON Q4 '25 Earnings Results & Recap Eton Pharmaceuticals reported total net revenues of $79.95M for the twelve months ended December 31, 2025, an increase from $39.01M in 2024, resulting in a gross profit of $42.74M.

0 · Reply

DonCorleone77 Mar. 19 at 8:16 PM

$ETON Eton Pharmaceuticals sees FY26 revenue at least $110M, consensus $105.25M "We are poised for another year of record financial results in 2026. For the full year, we expect to see revenue exceed $110 million and at least a 30% Adjusted EBITDA margin," concluded Brynjelsen.

0 · Reply

DonCorleone77 Mar. 19 at 8:15 PM

$ETON Eton Pharmaceuticals reports Q4 EPS 5c vs. (2c) last year Reports Q4 revenue $21.28M, consensus $20.58M. "It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio including INCRELEX, ALKINDI SPRINKLE, KHINDIVI, and GALZIN. The strong fourth quarter helped us cap off a transformational 2025. During the year we launched three major products, INCRELEX, GALZIN, and KHINDIVI, and delivered $80 million in total revenue, more than doubling our 2024 revenue," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

0 · Reply

bryantboy99 Mar. 19 at 7:58 PM

$ETON why didn't I buy more under $4?

0 · Reply

topstockalerts Mar. 19 at 7:42 PM

$ETON tends to react to catalysts, otherwise quiet. When it wakes up, it can move sharply.

0 · Reply

Jimbates22 Mar. 19 at 7:03 PM

$ETON to $25 and $VCX to $250 tomorrow.

0 · Reply

SpyVsSpy2 Mar. 19 at 6:10 PM

$ETON March Gladness…LFG!

0 · Reply

Market Cap	598.58M
Revenue (ttm)	39.01M
Net Income (ttm)	-3.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	20.36
Profit Margin	-9.79%
Debt to Equity Ratio	1.31

Volume	896,900
Avg Vol	295,752
Day's Range	N/A - N/A
Shares Out	26.82M
Stochastic %K	90%
Beta	1.19
Analysts	Strong Sell
Price Target	$31.00